SCHEMBL4292996

SCHEMBL4292996

Cc1ccccc1O[C@H]1CCN(C(=O)c2cccc(N3CCCNCC3)n2)C1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 2/20 0.44
PRKCQ Q04759 2/20 0.44
PRKCD Q05655 2/20 0.44
KMT2A Q03164 2/20 0.40
HRH3 Q9Y5N1 2/20 0.40
HCRTR1 O43613 1/20 0.40
HCRTR2 O43614 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
KDM5A P29375 1/20 0.39
RBP4 P02753 1/20 0.39
EPHX2 P34913 1/20 0.38
HTR2C P28335 1/20 0.38
ACACB O00763 2/20 0.37
SCD O00767 1/20 0.37
HSD11B1 P28845 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3470317 1.00 PRKCA (0.44) PRKCAPRKCQPRKCDKMT2AHRH3
SCHEMBL3470315 1.00 PRKCA (0.44) PRKCAPRKCQPRKCDKMT2AHRH3
SCHEMBL4295318 0.96 HCRTR1 (0.44) PRKCAPRKCQPRKCDKMT2AHRH3
SCHEMBL4295313 0.96 HCRTR1 (0.44) PRKCAPRKCQPRKCDKMT2AHRH3
SCHEMBL4297766 0.89 PRKCA (0.44) PRKCAPRKCQPRKCDKMT2AHRH3
SCHEMBL4293266 0.89 PRKCA (0.44) PRKCAPRKCQPRKCDKMT2AHRH3
SCHEMBL4294947 0.89 PRKCA (0.44) PRKCAPRKCQPRKCDKMT2AHRH3
Hydrochloric Acid SCHEMBL4290938 0.89 PRKCA (0.43) PRKCAPRKCQPRKCDKMT2AHRH3
Hydrochloric Acid SCHEMBL4290942 0.89 PRKCA (0.43) PRKCAPRKCQPRKCDKMT2AHRH3
SCHEMBL3467785 0.86 PRKCQ (0.44) PRKCQKMT2AHRH3HCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders PFIZER INC. 2009-08-06 US disclosed
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders PFIZER INC. 2009-08-06 US disclosed
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders PFIZER INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders HTR6, HTR5A, TPH1 PRKCA 3735/4885PRKCQ 2560/4885PRKCD 3188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.